Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Mundipharma Files Anesthetic Med Anerem for New Indication in Japan
September 28, 2023
- Sawai’s Revlimid Generic Gets MDS Nod; December Listing Eyed
September 28, 2023
- Lucentis, Rituxan Biosimilars Win Label Expansions
September 28, 2023
- Pfizer Rolls Out Alopecia Areata Drug Litfulo in Japan
September 28, 2023
- Ono, Adimab Join Hands to Discover Antibody Drugs for Cancer
September 28, 2023
- Regeneron to Make Japan Debut with Dupixent Copromotion
September 27, 2023
- Lilly’s Alzheimer’s Therapy Filed in Japan, Approval Eyed in 2024
September 27, 2023
- LEO Pharma’s Eczema Drug Adtralza Now Available in Japan
September 27, 2023
- CureApp’s Hypertension Therapeutic App Shows Effects in Clinical Setting
September 27, 2023
- Viatris Japan to Go After Drugs in All Phases of Life Cycle, Group Consolidation by Year-End: Chief
September 26, 2023
- Oncolys, Cornell University to Partner in IIT of Telomelysin Combo
September 26, 2023
- Takeda Files Low-Dose Form of Ninlaro in Japan
September 25, 2023
- LTL Pharma Sees “G1” LLP Price Cuts as Business Opportunity: President
September 22, 2023
- Viatris Files Cystinosis Med in Japan
September 22, 2023
- FDA Accepts Takeda’s Resubmission for Eosinophilic Esophagitis Drug
September 22, 2023
- Lecanemab to Serve as Gamechanger in Science, Treatments Set to Start by Year-End: Biogen Japan Chief
September 21, 2023
- Asahi Kasei, NCC Ink CAR-T Research Deal, Eye Launch for ATLL in 2027
September 21, 2023
- Shionogi’s Xocova Effective in High-Risk COVID Patients
September 20, 2023
- Hisamitsu Kicks Off Japan PII for Microneedle-Based Topical Sedation Drug
September 20, 2023
- Otsuka/Astex’s Oral AML Drug Nabs European OK
September 20, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…